



UNIT STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/086, 327	05/28/98	DURETTE	P 19965Y

<input type="checkbox"/>	HM22/0504	<input type="checkbox"/> EXAMINER
MOLLIE M. YANG		LUKTON, D
MERCK & CO., INC		
PATENT DEPT		<input type="checkbox"/> ART UNIT
P O BOX 2000		1653
RAHWAY NJ 07065-0907		<input type="checkbox"/> PAPER NUMBER
		DATE MAILED: 05/04/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
---------------	-------------	-----------------------	---------------------

09/086327

[REDACTED] EXAMINER

ART UNIT	PAPER NUMBER
----------	--------------

21

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

Please see the attached communication regarding this application.

Pursuant to the directives of paper No. 18 (filed 10/17/00), claim 17 has been cancelled, and claim 23 added. Claims 6-8, 11-16, 20-23 are pending.

Pursuant to the following Examiner's Amendment, claims 6-8, 11-16, 21-23 are allowable.

However, a reference relevant to the examination of this application may soon become available. *Ex parte* prosecution is SUSPENDED herewith.

*

An Examiner's Amendment to claims was discussed in an interview with Mollie Yang held 11/14/00. Since this application is now suspended, the claim amendments that are directed by this Examiner's Amendment have not been entered; the claims remain as they were prior to this communication. However, applicants may choose to make reference to this Examiner's Amendment in response to this, or any subsequent Office action. As discussed in the telephone interview, the changes to the claims that are directed by the Examiner's Amendment are as follows:

- In claim 21, immediately following formula Ia, the following phrase occurs:

“or a pharmaceutically acceptable salt thereof, wherein”

In this phrase, delete “pharmaceutically acceptable”
- Cancel claim 20.

- In claim 22, 22nd line from last, delete "norleucine;]",
and substitute therefor: - - norleucine; - - .
- In claim 22, 9th line from last, delete:
"N-[4-(benzoylamino)benzenesulfonyl)-(L)-prolyl-(L)-norleucine;"
and substitute therefor:
- - N-(4-(benzoylamino)benzenesulfonyl)-(L)-prolyl-(L)-norleucine; - - .

*

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton [phone number (703)308-3213].

An inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Christopher S. Low
CHRISTOPHER S. F. LOW
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600